SUNNYVALE, Calif. and
STOCKHOLM, July 13, 2015 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) and RaySearch Laboratories AB (publ)
(NASDAQ OMX Stockholm: RAY B) announced today they have signed a
long-term collaboration agreement which will allow Accuray to
co-market and offer the RayCare® oncology information
system (OIS) which is currently in development at RaySearch. Under
the contract, Accuray will have the opportunity to offer
RayCare® in several designated major radiation therapy
markets, making available a fully-integrated solution with the
TomoTherapy® and CyberKnife® System product
portfolios. RaySearch, known for its innovative, advanced and
user-friendly treatment planning software, RayStation®,
and Accuray, recognized for its innovative tumor treatments, are
partnering to provide the radiation oncology community with a
creative approach for delivering and managing precise radiation
therapy.
RayCare® is a next generation OIS developed from the
ground up by RaySearch to support the complex logistical challenges
in modern large-scale radiation therapy centers.
RayCare® integrates the high performance radiation
therapy algorithms available in RayStation® and adds
advanced features for clinical resource optimization, workflow
automation and adaptive radiation therapy. The system is expected
to be released in 2017.
"In today's complex healthcare environment it is becoming
increasingly important to deliver clinical excellence and
successful outcomes for cancer patients through radiation treatment
options, which are both effective and efficient," said Joshua H. Levine, president and chief executive
officer of Accuray. "Our goal in partnering with RaySearch is to
provide solutions that will enhance the integration of the
TomoTherapy and CyberKnife technologies with our customers'
oncology department workflow, enabling them to more easily manage
the large volumes of clinical data and to streamline their
patients' radiation treatments."
"The RaySearch and Accuray collaboration agreement brings
together two companies dedicated to providing clinicians with
innovative solutions which result in more effective radiation
therapy for cancer patients," said Johan
Lof, president and chief executive officer of RaySearch
Laboratories AB (publ). "We believe RayCare® has the
potential to set a new standard for oncology information systems
and will enable cancer centers to optimize their workflow and use
of resources to maximize the level of care they provide to their
patients."
About the CyberKnife and TomoTherapy Systems
The Accuray CyberKnife M6™ Series and TomoTherapy H™ Series
treatment solutions cover the entire spectrum of radiation therapy
needs. The CyberKnife M6 Series enables precise, high-quality,
high-dose distributions to be confidently delivered to the patient
with extreme accuracy over a minimum number of treatments, reducing
side effects and preserving patients' quality of life. The
CyberKnife System is the only robotic full-body radiosurgery system
available today. The TomoTherapy H Series efficiently enables
physicians to customize treatment plans for the entire range of
radiation therapy patients and disease types. Its innovative design
enables treatment plans to be delivered with integrated, daily CT
image guidance, enhancing accuracy and delivering highly precise,
intensity-modulated radiation for optimal sparing of healthy tissue
and critical structures.
Further information on Accuray, the CyberKnife and TomoTherapy
Systems is available at www.accuray.com.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to future growth, market
success, adoption of our new products, clinical benefits of our
technologies, patient outcomes and Accuray's leadership position in
radiation oncology innovation and technologies. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from expectations, including
but not limited to the risks detailed under the heading "Risk
Factors" in the company's report on Form 10-K, filed on
August 29, 2014, the company's
reports on Form 10-Q, filed on November 7,
2014, February 6, 2015 and
May 7, 2015, and the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company
that develops advanced software solutions for improved radiation
therapy of cancer. RaySearch markets the RayStation®
treatment planning system to clinics all over the world. In
addition, RaySearch's products are distributed through licensing
agreements with leading medical technology companies. RaySearch's
software solutions are used by over 2,500 clinics in more than 65
countries.
RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the
Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit
www.raysearchlabs.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/accuray-and-raysearch-announce-long-term-collaboration-agreement-regarding-the-raycare-oncology-information-system-300111978.html
SOURCE Accuray Incorporated